Logo Image
News|Articles|March 18, 2014

FDA Approves Eliquis to Reduce the Risk of Blood Clots

FDA approves Eliquis (apixaban) for DVT and PE in patients who have undergone hip or knee replacement surgery.

Bristol-Myers Squibb and Pfizer reported that FDA approved a supplemental new drug application (sNDA) for Eliquis (apixaban) for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery. This sNDA approval for Eliquis is supported by three clinical trials (the ADVANCE clinical trial program). The ADVANCE trials randomized more than 11,000 patients, with 5770 receiving Eliquis and 5755 receiving enoxaparin, to assess the safety and efficacy of Eliquis.

In December 2013, FDA accepted for review another sNDA for Eliquis for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE.

Source: Pfizer

Related to this article

View more
FDA
FDA's IND Pilot Puts CMC Review First
FDA opens applications for its Expedited IND Pilot, pairing sponsors with qualified research institutions to test rolling CMC review ahead of first-in-human trials.
Read more
Quality inspector walking through processing area with stainless tanks and tablet | Image Credit: ©Surachai -stock.adobe.com
Successful Internal Audit Planning and Execution
At the PDA/FDA Joint Regulatory Conference 2026, Helen Motamen, MS global head, Sanofi Quality Audit, Inspection, Intelligence & Advocacy, at Sanofi, provided advice for creating a strong internal audit program.
Read more